ALK and non-small cell lung carcinoma: The identification of molecular biomarkers (e.g., alterations in EGFR, ALK, ROS1 genes) that are druggable with targeted systemic therapies and the development of immune checkpoint inhibitors (ICIs) have modified the management and the prognosis of NSCLC, increasing the percentage of stage IV patients with an OMD and consequently improving the outcome [6,7].